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Abstract: A growing list of common and rare genetic risk variants are being implicated in schizophrenia susceptibility. 
As with other complex genetic disorders most of the variance in genetic risk is still to be attributed. What can be learned 
from progress to date? The available data challenges how we conceptualize schizophrenia and suggests strong aetiological 
links with other psychiatric and developmental disorders. With the identification of rare copy number risk variants 
implicating specific genes (e.g. VIPR2 and NRXN1) it is increasingly possible to investigate molecular aetiology in 
patient subgroups to establish whether schizophrenia represents one or many different disease processes. This review 
summarizes recent research progress and suggests how the tools of modern genomics and neuroscience can be applied to 
best understand this devastating disorder.  
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INTRODUCTION 
  The ‘shock of the new’ referred to a reflexive, premature 
and generally negative response provoked by the emergence 
of modern art [1]. Inevitably, with time, distance and 
perspective a more balanced consensus evolved as it does for 
other ‘new’ things. The early genomic data for schizophrenia 
provide a fascinating parallel where many responses have 
been prematurely negative [2] or focussed on what genome-
wide association studies (GWAS) didn’t find (the ‘missing 
heritability debate’) [3] rather than on the many novel, 
interesting findings that are emerging.  
  We believe that genomic and other research tools are 
available to help us come to grips with these findings. 
Translating them into pathophysiological insights will take 
time, but is important for several reasons. The onset of 
schizophrenia is typically in early adulthood, but the 
evolution and severity of symptoms, and course of illness are 
variable despite modern treatments. Schizophrenia is a 
public health problem as approximately 1% of the adult 
population are affected and life expectancy is reduced by an 
average of 20-25 years [4]. Because schizophrenia is 
substantially heritable, the search for risk genes is not new, 
but has faced significant obstacles.  
  Schizophrenia is diagnosed clinically based on a triad of 
symptom domains (DSM-IV) [5]. One of these symptom 
groups, psychosis (delusions and hallucinations), is almost 
ubiquitous during illness episodes. The second, involving 
disorganization of thinking and behavior, is also strongly 
associated with psychotic episodes. The final group of 
‘negative’ symptoms represents a loss of social function and 
volition and is more insidious and less amenable to current  
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therapeutics. Many patients are only ever affected in one or 
two of these domains and within domains, symptoms are 
also heterogeneous. Although clinically useful, it is uncertain 
how this diagnosis maps to underlying biology. The extent to 
which these symptom groups overlap with other psychiatric 
disorders, medical disorders [6], and even normal human 
experience [7] is underappreciated but striking (Fig. 1). 
  One implication is that psychosis may be an endpoint for 
many different pathological processes and even a variant of 
normal human experience in states of stress or restricted 
consciousness. Social, behavioural and cognitive 
abnormalities, which also feature in schizophrenia, overlap 
prominently with other disorders including learning 
disability and autistic spectrum disorders [8]. This symptom 
overlap causes ongoing controversy about how the clinical 
boundaries of the disorder should be drawn [9]. At the same 
time, a new and more radical view of schizophrenia, based 
on modern genomics is emerging. Many of the early findings 
detailed below have been surprising, even shocking, but 
(with the benefit of hindsight) should not have been entirely 
unexpected.  
1. SCHIZOPHRENIA THE PHENOTYPE 
  Given the rich genetic epidemiological literature, 
genetics has long offered the promise of insight into the 
molecular mechanisms involved in schizophrenia risk. 
Estimates based on twin-data suggest substantial heritability 
(h2~0.80-0.85) [10] although many patients have no first-
degree relatives with the disorder. Model fitting of twin data 
indicates that schizophrenia overlaps with another major 
psychotic condition, bipolar disorder [11]. In fact, data from 
high-risk studies of the offspring of mothers with 
schizophrenia suggest that this liability extends to include 
other psychotic disorders and related personality disorders, 
termed the ‘schizophrenia spectrum disorders’ [12]. This 
overlap is not reflected in the early molecular genetics Progress in Schizophrenia Genomics  Current Genomics, 2011, Vol. 12, No. 7    517 
literature for several reasons. Schizophrenia is a clinical 
diagnosis and in some cases it can be difficult to reach a 
clear diagnosis, for example in cases with mixed psychotic 
and affective symptoms [13]. Because of concern about 
misclassification errors, these types of cases were excluded 
from genetics analysis. Researchers were also concerned that 
extending studies beyond the established heritable core 
diagnosis would reduce study power by including cases with 
less clear genetic aetiology.  
  A remarkable exception to this orthodoxy involved the 
mapping of the gene Disrupted-in-Schizophrenia-1 (DISC1), 
which was identified in a large Scottish kindred. A balanced 
translocation between chromosome 1 and 11 strongly co-
segregates with mental disorder in this family. The index 
case had a diagnosis of conduct disorder and within the 
family, 18 of 29 (70%) translocation carriers had a major 
mental disorder (including schizophrenia, bipolar disorder or 
major depressive disorder), whereas none of the non 
translocation carriers had such a diagnosis [14]. More than 
three decades of follow-up in the family indicates that this 
mutation has a large effect on liability to both schizophrenia 
and mood disorder in carriers. Recent large-scale 
epidemiological studies across disorders, demonstrate 
conclusively that this is a more general phenomenon. In a 
study of more than 9 million Swedish individuals, 
Lichtenstein and colleagues [15] confirmed that first degree 
relatives of probands with either schizophrenia or bipolar 
disorder are at increased risk of both disorders. The extent of 
shared liability extends to increased risk of autism [16] and a 
broad range of mental disorders in relatives of schizophrenia 
patients [17]. Rates of schizophrenia are also known to be 
three times higher in people with intellectual disability. 
Collectively, this data suggests that genetic liability 
represented by schizophrenia substantially overlaps with 
other psychiatric and neurodevelopmental disorders.  
2. WHAT IS THE GENETIC MODEL? 
  Based on genetic epidemiological data of risk in different 
classes of relatives it was suggested that several (or more) 
risk genes interacted with each other and environmental risk 
to cause schizophrenia [18]. This model, framed the common 
disease common variant (CDCV) hypothesis but was 
challenged by an opposing view that susceptibility involved 
the influence of rare genetic variants, the common disease 
rare variant (CDRV) hypothesis. An added dimension to the 
model is whether schizophrenia represents a single disease 
entity or many different disease processes or molecular 
mechanisms; a rare disease rare variant (RDRV) model. 
Only in the last few years have the molecular methods 
required to begin testing these models become available; 
what is emerging is a genetic architecture involving both 
common and rare risk variation.  
  Early molecular studies, using linkage and candidate 
gene association studies (Zone A in Fig. 2), excluded large, 
common single gene effects. The recent genome-wide 
association studies (GWAS) discussed in the next section 
have started to confirm some common risk variants of 
modest effect (Zone B in Fig. 2). From studies of copy 
number variation we know that examples like the DISC1 
translocation, or 22q11.2 deletion syndrome (discussed 
below) are not unique oddities within ‘mainstream’ 
schizophrenia. A growing number of rare variants are being 
discovered and large-scale genome sequencing will allow 


















Fig. (1). Within the smaller triangle are the core symptom domains of schizophrenia. The larger triangle includes key comorbidities. Each of 
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(Zone C in Fig. 2). It remains an open question as to whether 
the risk variants identified contribute to one or many 
different molecular mechanisms and represent one or many 
diseases.  
2.1. Common Variant Common Disorder 
  In the pre-genome era, linkage and candidate gene 
studies provided a relatively meager return of potential 
susceptibility loci for schizophrenia and putative candidate 
genes. This list of candidate genes (including Dysbindin and 
Neuregulin-1) has received some degree of statistical 
support. A more definitive list may be found on the SZGene 
database [20]. As these variants are in some cases poorly 
assayed by the platforms used for the larger genome-wide 
association studies (GWAS) detailed below, their status 
remains equivocal [21].  
  A series of (GWAS) [22-25] and a large meta-analysis of 
GWAS data, conducted through the Psychiatric GWAS 
Consortium (PGC), have provided genome-wide significant 
evidence for at least nine susceptibility loci as demonstrated 
in Table 1.  
  As has been the consistent theme across common 
disorders, initial schizophrenia GWAS findings explain only 
a modest proportion of the variance in susceptibility. A 
significant proportion of the remainder may involve a 
polygenic component including hundreds, if not thousands, 
of common alleles of small effect. Using a polygene score 
method, the International Schizophrenia Consortium [23] 
identified substantial overlap in common putative risk alleles 
of small effect across both schizophrenia and bipolar 
samples and estimated that these explained at least one-third 
of total variation in liability. From the emerging GWAS 
data, many of the associated loci appear to confer liability to 
both schizophrenia and bipolar disorder [27]. 
2.2. Rare Variants and Schizophrenia 
  The 22q11.2 deletion syndrome (22q11.2DS; also known 
as velo-cardio-facial syndrome (VCFS)) is caused by the 
most common large microdeletion in the human genome and 
has an incidence of 1 in ~4000 live births. The phenotype is 
highly variable and can affect multiple organs and tissues, 
but carriers have a 30-fold increased risk of schizophrenia 
[28]. An increased, if less substantial risk of schizophrenia is 
reported in Marfan syndrome [29] and conversely a reduced 
risk is reported in Down syndrome [8]. Until relatively 
recently these findings have been seen as novel curiosities 
that make a limited contribution to what is a relatively 
common disorder.  
  As we became able to detect submicroscopic deletions 
and duplications in the human genome [30-31] and 
discovered these to be more common than expected, this has 
changed. A seminal paper by Walsh and colleagues [32] 
identified an increased rate of novel deletions and 
duplications of genes in schizophrenia cases, particularly 
young onset cases. These mutations were reported to 
disproportionately disrupt signaling networks controlling 
neurodevelopment. Two large consortia studies identified 
association with copy number change at chromosome 1q21.1 
and deletions of chromosome15q13.3 [33-34]. Subsequent 
studies have reported evidence for association with more 
CNVs implicating 2p16.3, 3q29 and 15q11.2 deletions and 
duplications of 7q36.3 and 16p11.2. Relative to the common 
SNP variants these mutations are rare and cumulatively they 
involve 2-3% of cases, so far [35]. Many of these span many 
genes, but the 2p16.3 and 7q36 loci implicate specific genes, 
NRXN1 and VIPR2 respectively, which bring them sharply 
into view for further investigation.  
  Unexpectedly, all of these CNVs confer susceptibility to 
















Fig. (2). Genetic models for disease. Zone A showing common variants of high penetrance. Genome wide association studies have identified 
common, low penetrance, risk variants as demonstrated in Zone B. Zone C shows rare risk variants which will be more readily detected by 
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retardation, autism, ADHD, seizure disorders and obesity 
[36-39]. As an example, the 15q13.3 increases risk for a 
wide range of clinical features including schizophrenia, 
autism, seizure disorder, learning disability and cardiac 
malformations, but a subset of carriers have no discernable 
clinical findings [40]. By contrast, CNVs appear to be less 
common in bipolar disorder than in control populations [41]. 
This is not simply related to the size of the genomic region; 
at the VIPR2 locus, implicated in schizophenia but also 
autism cases, the overlapping copy variable region was 
localized to exons 3 and 4 of the gene [42]. For each of these 
loci further studies are required to identify the range of 
phenotypic expression that exists and the disease 
penetrances. The form of phenotype expression may reflect 
the influence of other genetic (e.g. common or rare variants) 
or environmental factors, or other stochastic effects during 
neurodevelopment.  
3. DISCUSSION 
  Genomic data is re-shaping our understanding of 
schizophrenia. As with other common disorders, common 
variants of small effect are being implicated. Some of these 
variants appear to also contribute risk to other psychiatric 
phenotypes, in particular bipolar disorder. A point of 
difference from bipolar disorder, which links schizophrenia 
to other neurodevelopmental disorders, is the identified 
contribution of rare CNVs, which collectively may account 
for some proportion of total susceptibility to schizophrenia 
within the population.  
  It is too early to know whether the contribution of this 
rare variation is as significant as it is proving to be in autism 
[35, 43]. However, these data represent a starting point to 
test new hypotheses using the modern tools of genomics and 
neuroscience research to make real breakthroughs in our 
understanding of the molecular mechanisms involved.  
3.1. Reshaping How We Define the Disorder 
  The few pieces of the genetic puzzle that we now have, 
suggest a radical re-shaping of the clinical boundaries that 
define the disorder may be required. At a genetic level 
schizophrenia overlaps with both adult and childhood 
disorders of a neurodevelopmental aetiology. Knowing this 
allows novel studies to assess the biological underpinnings 
of these clinical entities. Further studies of common 
variation, for example, using polygene analyses and cross-
disorder meta-analyses (currently underway within the 
Psychiatric GWAS Consortium) will clarify the extent of this 
overlap. The range of phenotypes associated with known 
rare variants suggests that its reasonable to extend GWAS 
studies of common variation to include related medical 
phenotypes (e.g. seizure disorder). This approach may not go 
far enough. As previously discussed, a striking number of 
different biological causes can lead to schizophrenia 
symptoms; this may involve many brain circuits. The 
discovery of rare, highly penetrant mutations makes feasible 
a reverse approach, where biological dissection of these 
mutations, rather than heterogeneous clinical phenotypes can 
shape understanding of causation for at least a subset of 
patients currently defined as having schizophrenia.  
3.2. Larger, Bigger, Better? 
  The Psychiatric GWAS Consortium is now trying to 
extend its sample to increase power to detect more modest 
genetic effects. The pace of gene discovery so far is typical 
of complex disease [44] and data from other disorders 
suggests that, if successful in doubling the current sample (to 
>40,000 cases), this is likely to generate many new loci [45]. 
An obvious question is what can be learned from genetic 
variants that individually increase risk of the disorder from 1 
to 1.1%? The endpoint of GWAS studies is the discovery of 
biological pathways underlying complex disorders, rather 
than individual risk loci. For other disorders and traits, 
including inflammatory bowel disease and body mass, 
confirmed risk genes fall into specific molecular pathways 
which extend our understanding of the genetics and biology 
of these traits [46-47]. Arguably this is already happening in 
schizophrenia where both the micro-RNA MIR137 and zinc 
finger protein ZNF804A genes appear to be involved in 
Table 1.  Genome-Wide Significant Schizophrenia Loci 
Chr  Gene Name  SNP   Reference 
1p21.3  microRNA 137 (MIR137)   rs1625579  [23, 26] 
2q32  zinc finger protein 804A (ZNF804A)   rs1344706  [22] 
2q32.3  prostate-specific transcript 1 (PCGEM1) rs17662626    [26] 





8p21.3  matrix metallopeptidase 16 (MMP16)   rs7004633  [26] 
8p23.2  CUB and Sushi multiple domains 1 (CSMD1) gene  rs10503253   [26] 
10q24.32  cyclin M2 (CNNM2) rs7914558  [26] 
11q24 neurogranin  (NRGN)   rs12807809  [24] 
18q21  transcription factor 4 (TCF4)   rs9960767  [24] 520    Current Genomics, 2011, Vol. 12, No. 7  Moore et al. 
regulating the function of other genes. MIR137 is a 
particularly promising example, as it is implicated in the 
regulation of adult neurogenesis [48] and four of the eleven 
loci identified in the PGC meta-analyses of schizophrenia 
and bipolar disorder are predicted MIR137 target [49]. 
  Having better estimates of small effect sizes will also be 
useful for molecular pathway based analyses of the GWAS 
data [50]. In principle, jointly examining whether a group of 
related genes in a functional pathway are associated with a 
disease may be more powerful than testing individual 
markers. Before GWAS studies, this approach was hampered 
by our limited understanding of biology: candidate genes for 
analysis stemmed from existing hypotheses (e.g. of 
glutamatergic dysfunction), leading analyses to the circular 
conclusion that ‘enrichment’ for association within these 
genes confirmed the hypothesis. A number of different 
pathway based methods have been applied to schizophrenia 
GWAS data [51-53]. Although these studies overlapped in 
the samples examined, with the exception of pathways 
involved in cell adhesion [51, 53], there is little agreement as 
to which pathways are being implicated. This may reflect 
differences in methodology, including different pathways 
being examined, but is also likely to reflect ‘noise’ in the 
data due to the many false positive findings in smaller 
datasets, where measures of individual risk at a SNP-level 
are imprecise. If this is the case, testing with larger samples 
may provide more consistent signals and be valuable in 
improving pathway annotation. Having better estimates of 
common, small genetic risk effects may also address a 
second important question. If there are a large number of 
common risk variants within the population, does the total 
number of variants carried by an individual predict risk or 
outcome for the disorder? A question that could be addressed 
by modelling total risk SNP burden.  
3.3. Smaller, Better, Best? 
  From a recent review of the emerging CNV literature 
<5% of schizophrenia patients carry at least one of the risk 
CNVs identified to date [35]. Assessing their pathogenic 
significance is still a challenge (this issue is discussed more 
fully in Lee & Scherer, 2010 [54]). For instance, recurrent 
CNVs involving the putative schizophrenia risk genes 
NRXN1 and erbB4 are reported in control populations. More 
information on the prevalence in the general population and 
the phenotypic consequences of carrying these mutations for 
diagnosis and prognosis is urgently required. With the 
exception of 22q11.2DS we know little about their clinical 
features [28]. Some of these mutations may have a core of 
shared phenotypic features, as is the case with certain ASDs 
(e.g. Prader-Willi/Angelman syndrome) but others may have 
a wide range of phenotypic effects.  
  Whole genome sequencing data will become available 
for hundreds, if not thousands of schizophrenia patients in 
the next couple of years. Sampling all classes of rare genetic 
mutations may substantially increase our estimation of how 
important rare mutations are in the aetiology of 
schizophrenia. Based on deep re-sequencing data, a recent 
study suggests that there is an increased rate of potentially 
deleterious de novo mutations in schizophrenia and autism 
patients [55]. Attaching pathogenic significance to rare, or 
even private, point mutations will be even more challenging 
than for CNVs. The likely first step will be to assess the full 
spectrum of potentially causative variants at known common 
(e.g. ZNF804A and TCF4) and rare risk genes (e.g. VIPR2 
and  NRXN1). A second step will be to establish whether 
implicated genes can be logically grouped based on their 
biology, and whether other genes in these pathways also 
harbor risk mutations (as was the case for DISC1 [56]). This 
will bring into focus much smaller, more detailed studies to 
assess the impact of particular mutations within carriers and 
their families, to establish if they are inherited or are 
occurring de novo and assessment of whether mutations can 
be grouped, based on biology, for phenotypic or 
pharmacogenetics studies.  
  Other study designs may also be informative. One 
possibility being to sample families affected by a 
‘syndromal’ form of schizophrenia who have additional 
phenotypes including learning disability, autism, seizure 
disorder or other developmental difficulties. This approach 
has been remarkably successful for severe 
neurodevelopmental disorders, where a genetic cause is 
identifiable in more than 60% of cases [57]. We can learn 
several lessons from these studies. Firstly, mutations that 
block, or impair formation of full-length proteins have more 
severe phenotypic consequences. If these types of mutations 
contribute appreciably to schizophrenia they will be the most 
easily detected by whole-genome sequencing analysis. 
Secondly, for any gene there is likely to be a spectrum of 
mutations within the human population [58]. For genes 
where null mutations are known to cause severe 
neurodevelopmental phenotypes affecting gross brain 
structure (e.g. DCX), less deleterious mutations of the same 
gene are associated with more subtle brain phenotypes [59]. 
It may be reasonable to test genes known for involvement in 
severe brain developmental phenotypes for less deleterious 
mutations, which could be relevant to schizophrenia or 
psychosis. As an example, Pitt-Hopkins Syndrome (PTHS), 
which is a developmental disorder with severe learning 
disability, can be caused by haploinsufficiency of TCF4 or 
deletions/missense mutations of NRXN1. Both of these genes 
are implicated in schizophrenia [60]. 
3.4. One or Many Diseases?  
  At this point we do not know whether the term 
‘schizophrenia’ captures one or many different diseases. We 
have identified common risk variants, which may implicate 
many different brain circuits and predispose to psychosis 
through one or many different mechanisms involving 
information processing or salience i.e. one’s ability to attend 
to the most relevant or important aspect of available sensory 
information. Is this a generic psychosis risk for some or all 
of the disorders that predispose to psychosis (in Fig. 1)? The 
identification of rare variants with much larger effects on 
individual risk raises further questions. Do the deletions at 
VIPR2 and NRXN1 represent entirely different diseases? If 
so, do they implicate different signaling pathways or do they 
converge on a common molecular mechanism, for example, 
involving GSK3ß signaling? Future models of psychotic 
disorder may be defined by genetic risk, where groups with 
higher rates of risk will be identified and possibly defined as 
having distinct diseases at a molecular level (e.g. Fig. 3). Progress in Schizophrenia Genomics  Current Genomics, 2011, Vol. 12, No. 7    521 
CONCLUSION 
  The modern research toolbox allows mutations to be 
studied using approaches that can address these questions. 
For example, as demonstrated by Brennand and colleagues 
[61], human cellular models of schizophrenia are 
increasingly feasible. They have reported on a cellular model 
of schizophrenia generated using neuron–type cells 
generated using human induced pluripotent stem cell 
(hiPSC) technology from schizophrenia patients. Combined 
with gene expression profiling this identified altered 
expression of many components of the cyclic AMP and 
WNT signaling pathways in a small number of patients. As 
the authors acknowledge, this analysis assumes that 
schizophrenia is one disease. Applying this approach using 
patients grouped by mutation is a potentially powerful way 
of addressing the question of whether ‘schizophrenia’ 
involves one or many disease processes. Modern imaging 
methods make it possible to examine neural circuitry, using 
diffusion tensor imaging, in these same subjects. In parallel, 
these same mutations can be modeled directly in animal 
systems to generate cellular phenotypes and investigate 
neural circuits in vivo using viral tracing [62] and 
optogenetics [63] methods.  The application of these 
approaches, with better models, promises new insights into 
molecular aetiology and potentially novel therapeutics. From 
some future perspective the diagnosis and treatment of 
neurodevelopmental disorders based on clinical 
symptomatology may appear shocking indeed.  
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